Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
50 hedge funds and large institutions have $92M invested in Viracta Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 7 closing their positions.
923% more capital invested
Capital invested by funds: $9M → $92M (+$83M)
257% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 7
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
52% more funds holding
Funds holding: 33 → 50 (+17)
16% more call options, than puts
Call options by funds: $925K | Put options by funds: $800K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$27.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$15.8M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$8.66M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$6.75M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$6.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aisling Capital Management
New York
|
-$2.01M |
| 2 |
RM
RP Management
New York
|
-$347K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$182K |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$154K |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$106K |
VIRX Hedge Fund Activity: Q1 2021 in Review
50 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q1 2021, worth a combined $92M — up 923% from $9M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new VIRX positions and 7 closed out — a net gain of 18 holders — while 14 added to existing stakes and 9 trimmed.
The largest buyer was BVF Inc, adding an estimated $27.1M. The largest seller was Aisling Capital Management, exiting entirely with an estimated $2.01M sold.
- 50 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q1 2021, up from 33 in Q4 2020.
- Funds reported $92M of Viracta Therapeutics, Inc. Common Stock stock for Q1 2021, up 923% quarter-over-quarter.
- 25 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q1 2021 and 7 closed out, a net change of +18 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q1 2021 was BVF Inc, an estimated $27.1M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q1 2021 was Aisling Capital Management, an estimated $2.01M sold.
Based on aggregated 13F filings for Q1 2021.